Small Molecule Deal Benchmarks in Women's Health

Median Upfront

$326M

Range: $169M - $481M

Total Deal Value

$1.8B

Range: $1.1B - $2.5B

Royalty Rate

7.9% - 15.8%

Tiered up to 19.8%

Dev Milestones

$321M

Range: $206M - $436M

Model Your Deal

Market Analysis

Small Molecule therapies in women's health have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in women's health is $326M, with total deal values reaching $1.8B. Development milestones average $321M, while regulatory milestones contribute $336M.

The women's health small molecule landscape is characterized by moderate competitive intensity with significant historical underinvestment creating unmet need. Novel hormonal approaches, non-hormonal alternatives for menopause, and precision medicine in endometriosis are driving renewed deal-making activity. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule women's health deals range from 7.9% to 15.8% at the base tier, with tiered escalation reaching 11.9%-19.8% on blockbuster sales. Commercial milestones averaging $803M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule women's health licensing deal?

Based on our analysis, Phase 2 small molecule licensing deals in women's health average $326M in upfront payments, with a range of $169M to $481M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for small molecule women's health transactions?

The median total deal value for Phase 2 small molecule assets in women's health is $1.8B, ranging from $1.1B to $2.5B. This includes development milestones ($321M), regulatory milestones ($336M), and commercial milestones ($803M).

What royalty rates are standard for small molecule deals in women's health?

Base royalty rates for small molecule women's health transactions range from 7.9% to 15.8%, with tiered escalations reaching 11.9%-19.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in small molecule women's health deals?

Small Molecule women's health deals allocate approximately 82% of total deal value to milestones. Development milestones ($321M) make up the largest share, followed by commercial milestones ($803M) and regulatory milestones ($336M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Small Molecule Deal Benchmarks in Women's Health

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Monoclonal Antibody in Women's Health

Peptide Therapeutic in Women's Health

Small Molecule in Oncology

Small Molecule in Neurology

Ready to Calculate Your Deal Terms?